Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society... | May 9, 2023